Janssen Reports Results of Ponesimod in P-III OPTIMUM Study for Relapsing Multiple Sclerosis

Shots:

• The P-III OPTIMUM study involves assessing of Ponesimod (20 mg) vs Aubagio (teriflunomide, 14mg) in 1,133 patients with relapsing multiple sclerosis for 108 weeks
• The study resulted in meeting 1 EPs of annualized relapse rate (ARR) up to the end of the study and most of its 2 EPs with no new observed signals
• Ponesimod is a selective sphingosine-1-phosphate receptor 1 (S1P1) modulator, inhibiting S1P activity and reduces the number of circulating lymphocytes with its anticipated EMA’s approval for relapsing MS in H2’19

Click here to­ read full press release/ article | Ref: Janssen| Image: Opthalmology Innovation Summit